论文部分内容阅读
目的探讨p53和鼠双微粒体2(murine double minute 2,MDM2)在肾母细胞瘤中的表达,以及其在疾病发生、发展中的作用。方法 36例肾母细胞瘤患者的手术组织标本36份为肾母细胞瘤组,以相应瘤旁正常肾组织标本12份为对照组。采用免疫组织化学EliVision法检测2组P53蛋白和MDM2蛋白表达情况;比较不同临床分期、预后、病理类型肾母细胞瘤P53和MDM2蛋白表达差异,分析MDM2与p53的相关性。结果肾母细胞瘤组P53蛋白阳性表达率(30.6%)及MDM2蛋白阳性表达率(41.7%)高于对照组(0、8.3%)(P<0.05);预后良好型肾母细胞瘤P53蛋白和MDM2蛋白阳性率分别为15.4%、23.1%,低于预后不良型(70.0%、90.0%)(P<0.05);P53和MDM2蛋白在临床Ⅰ期、Ⅱ期肾母细胞瘤及4个不同组织学分型肾母细胞瘤的表达差异无统计学意义(P>0.05);肾母细胞瘤中MDM2蛋白与P53蛋白表达呈正相关(c=0.663,P=0.000)。结论 P53蛋白及MDM2蛋白阳性表达可用于判断肾母细胞瘤细胞分化程度,但不能作为临床分期的参考指标;p53和MDM2阳性表达与肾母细胞瘤的发生、发展有关。
Objective To investigate the expression of p53 and murine double minute 2 (MDM2) in Wilms’ tumor and its role in the development and progression of the disease. Methods Thirty - six cases of nephroblastoma from 36 patients with nephroblastoma were selected as the control group. The expression of P53 protein and MDM2 protein in two groups were detected by immunohistochemical EliVision method. The differences of P53 and MDM2 protein expression between different clinical stage, prognosis and pathological types were compared, and the correlation between MDM2 and p53 was analyzed. Results The positive expression rates of P53 protein and MDM2 protein in glioma group were higher than those in control group (P <0.05). The positive rates of P53 protein And MDM2 protein were 15.4% and 23.1% respectively, lower than those with poor prognosis (70.0% and 90.0%) (P <0.05). The positive rates of P53 and MDM2 protein in stage Ⅰ and Ⅱ nephroblastoma and in 4 different There was no significant difference in the histological type of nephroblastoma (P> 0.05). The expression of MDM2 protein in nephroblastoma was positively correlated with the expression of P53 (c = 0.663, P = 0.000). Conclusion The positive expression of P53 protein and MDM2 protein can be used to determine the degree of nephroblastoma differentiation, but can not be used as a reference for clinical staging. The positive expression of p53 and MDM2 is associated with the occurrence and development of nephroblastoma.